Astrana Health - ASTH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $46.33
  • Forecasted Upside: 15.95%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$39.96
▼ -0.01 (-0.03%)

This chart shows the closing price for ASTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Astrana Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASTH

Analyst Price Target is $46.33
▲ +15.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Astrana Health in the last 3 months. The average price target is $46.33, with a high forecast of $50.00 and a low forecast of $44.00. The average price target represents a 15.95% upside from the last price of $39.96.

This chart shows the closing price for ASTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Astrana Health. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2024Stifel NicolausLower TargetBuy ➝ Buy$50.00 ➝ $45.00Low
3/1/2024Truist FinancialBoost TargetHold ➝ Hold$41.00 ➝ $44.00Low
2/26/2024Jefferies Financial GroupInitiated CoverageBuy$50.00Low
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/29/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Astrana Health logo
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.
Read More

Today's Range

Now: $39.96
Low: $39.47
High: $40.64

50 Day Range

MA: $39.45
Low: $36.56
High: $42.56

52 Week Range

Now: $39.96
Low: $28.86
High: $45.71

Volume

111,536 shs

Average Volume

152,549 shs

Market Capitalization

$2.24 billion

P/E Ratio

30.27

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Astrana Health?

The following sell-side analysts have issued stock ratings on Astrana Health in the last twelve months: Jefferies Financial Group Inc., Stifel Nicolaus, and Truist Financial Co..
View the latest analyst ratings for ASTH.

What is the current price target for Astrana Health?

3 Wall Street analysts have set twelve-month price targets for Astrana Health in the last year. Their average twelve-month price target is $46.33, suggesting a possible upside of 15.9%. Jefferies Financial Group Inc. has the highest price target set, predicting ASTH will reach $50.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $44.00 for Astrana Health in the next year.
View the latest price targets for ASTH.

What is the current consensus analyst rating for Astrana Health?

Astrana Health currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ASTH.

What other companies compete with Astrana Health?

How do I contact Astrana Health's investor relations team?

Astrana Health's physical mailing address is 1668 S. GARFIELD AVENUE 2ND FLOOR, ALHAMBRA CA, 91801. The company's listed phone number is 626-282-0288 and its investor relations email address is [email protected]. The official website for Astrana Health is www.apollomed.net. Learn More about contacing Astrana Health investor relations.